Business Description
Mercury Biopharmaceutical Corp
ISIN : TW0006932007
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.77 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -1.09 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 61.43 | |||||
Beneish M-Score | -3.52 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -262.2 | |||||
3-Year EPS without NRI Growth Rate | -280.3 | |||||
3-Year FCF Growth Rate | -308.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.28 | |||||
9-Day RSI | 35.83 | |||||
14-Day RSI | 34.08 | |||||
6-1 Month Momentum % | -23.44 | |||||
12-1 Month Momentum % | -33.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 42.21 | |||||
Quick Ratio | 42.21 | |||||
Cash Ratio | 40.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -58.4 | |||||
Shareholder Yield % | -5.35 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 57.31 | |||||
Operating Margin % | -4423.04 | |||||
Net Margin % | -4241.63 | |||||
FCF Margin % | -5393.61 | |||||
ROE % | -13.4 | |||||
ROA % | -11.66 | |||||
ROIC % | -47.68 | |||||
ROC (Joel Greenblatt) % | -53.4 | |||||
ROCE % | -11.68 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3916.67 | |||||
PB Ratio | 12.58 | |||||
Price-to-Tangible-Book | 12.63 | |||||
EV-to-EBIT | -106.74 | |||||
EV-to-EBITDA | -117.86 | |||||
EV-to-Revenue | 4453.85 | |||||
EV-to-FCF | -85.56 | |||||
Price-to-Net-Current-Asset-Value | 16.79 | |||||
Price-to-Net-Cash | 17.54 | |||||
Earnings Yield (Greenblatt) % | -0.93 | |||||
FCF Yield % | -1.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Mercury Biopharmaceutical Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 1.033 | ||
EPS (TTM) (NT$) | -0.11 | ||
Beta | 0 | ||
Volatility % | 29.59 | ||
14-Day RSI | 34.08 | ||
14-Day ATR (NT$) | 0.973315 | ||
20-Day SMA (NT$) | 13.315 | ||
12-1 Month Momentum % | -33.55 | ||
52-Week Range (NT$) | 10.1 - 27.35 | ||
Shares Outstanding (Mil) | 415.96 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mercury Biopharmaceutical Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mercury Biopharmaceutical Corp Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
Mercury Biopharmaceutical Corp Frequently Asked Questions
What is Mercury Biopharmaceutical Corp(ROCO:6932)'s stock price today?
When is next earnings date of Mercury Biopharmaceutical Corp(ROCO:6932)?
Does Mercury Biopharmaceutical Corp(ROCO:6932) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |